Image: Public domain | via Wikimedia Commons
Hua Xuande, aged 82, is a prominent figure in the pharmaceutical industry as the chair of Zhejiang ZoneBanner Jiuzhou Group. He is the controlling shareholder of Zhejiang Jiuzhou Pharmaceutical, a Shanghai-listed company. His wealth source is pharmaceuticals. The company has made acquisitions, including U.S.-based PharmAgra Labs, to expand production. Hua Xuande and his family's net worth is estimated at $1.4 billion.
Information on Hua Xuande's early life and career is limited. However, he chairs Zhejiang ZoneBanner Jiuzhou Group, which controls Zhejiang Jiuzhou Pharmaceutical. The company is involved in the manufacturing and distribution of pharmaceuticals.
Hua Xuande's success is primarily tied to his leadership of Zhejiang ZoneBanner Jiuzhou Group and its control of Zhejiang Jiuzhou Pharmaceutical. In September 2019, Jiuzhou Pharmaceutical acquired U.S. pharmaceutical ingredient firm PharmAgra Labs, and in the same year, it took over a Chinese subsidiary of Swiss pharmaceutical maker Novartis to expand its production capabilities.
The key business strategy appears to be focused on expanding production through acquisitions and strategic partnerships. The acquisition of PharmAgra Labs and the subsidiary of Novartis indicates a focus on growth and expanding market share within the pharmaceutical sector.
Information about specific philanthropic initiatives and amounts is unavailable.
Currently chairs the company and controls Shanghai-listed pharmaceutical supplier Zhejiang Jiuzhou Pharmaceutical.
Jiuzhou Pharmaceutical acquired U.S. pharmaceutical ingredient firm PharmAgra Labs.
Jiuzhou Pharmaceutical took over a Chinese subsidiary of Swiss pharmaceutical maker Novartis.
